Chinese General Practice ›› 2022, Vol. 25 ›› Issue (23): 2819-2835.DOI: 10.12114/j.issn.1007-9572.2022.01.304

Special Issue: 指南/共识最新文章合集 泌尿系统疾病最新文章合集 安全用药最新文章合集

• Guide·Consensus •     Next Articles

Chinese Expert Consensus on Medication Safety in Polypharmacy in Type 2 Diabetics with Chronic Kidney Disease

  

  • Received:2022-05-18 Revised:2022-05-26 Published:2022-08-15 Online:2022-06-15
  • About author:
    Chinese Medical Association Clinical Pharmacy Branch. Chinese expert consensus on medication safety in polypharmacy in type 2 diabetics with chronic kidney disease[J]. Chinese General Practice, 2022, 25 (23) : 2819-2835.

2型糖尿病合并慢性肾脏病患者多重用药安全中国专家共识

  

  • 作者简介:
    中华医学会临床药学分会. 2型糖尿病合并慢性肾脏病患者多重用药安全中国专家共识[J]. 中国全科医学,2022,25(23):2819-2835.[www.chinagp.net]
  • 基金资助:
    国家重点研发计划"主动健康和老龄化科技应对"重点专项——老年常见病多重用药风险管控体系的研究和应用示范项目(2020YFC2005500); 老年常见病多重用药安全指南知识图谱及高风险药物管理研究(2020YFC2005502)

Abstract:

Diabetes is a serious public health problem worldwide. The prevalence of chronic kidney disease (CKD) secondary to type 2 diabetes mellitus (T2DM) is growing with the increase of T2DM prevalence. There is no comprehensive guideline on medication safety in polypharmacy in patients with T2DM-related CKD. This consensus provides guidance on safety issues in polypharmacy for clinical pharmacists and Chinese patients with T2DM-related CKD, and a summary of the information on usage and dosage, and related pharmaceutical characteristics of drugs as well as medication for special populations for supporting clinical medical workers in delivering standardized medication services.

Key words: Diabetes mellitus, type 2, Chronic kidney disease (CKD), Renal insufficiency, chronic, Polypharmacy, Expert consensus, Guideline

摘要:

糖尿病已成为一个严重的全球公共卫生问题,随着2型糖尿病(T2DM)患病率的增加,T2DM合并慢性肾脏病(CKD)发病率也呈上升趋势。目前国内外未见较为全面的T2DM合并CKD患者的临床多重用药安全指南。本共识旨在针对T2DM合并CKD患者临床多重用药安全问题,为中国的临床药师与患者提供相关指导意见,并汇总用法用量、相关药学特点、特殊人群用药等信息,服务于临床医护人员规范化用药需求。

关键词: 糖尿病, 2型, 慢性肾脏病, 肾功能不全, 慢性, 多重用药, 专家共识, 指南